Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms
New drug development is a high-risk venture, but if successful, will bring great revenues to those willing to accept the risk. In the field of urology, in particular for lower urinary tract symptoms (LUTS), the recent successful landing of drugs (e.g., mirabegron, botulinum toxin A, and tadalafil) h...
Main Authors: | Kyung Jin Chung, Benjamin I. Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Continence Society
2017-06-01
|
Series: | International Neurourology Journal |
Subjects: | |
Online Access: | http://www.einj.org/upload/pdf/inj-1734928-464.pdf |
Similar Items
-
Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder
by: Chung-Cheng Wang, et al.
Published: (2015-03-01) -
Improvement of Persistent Detrusor Overactivity through Treatment with a Phytotherapeutic Agent (WSY-1075) after Relief of Bladder Outlet Obstruction
by: Su Jin Kim, et al.
Published: (2018-05-01) -
Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms
by: Vasileios Sakalis, et al.
Published: (2021-03-01) -
Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity
by: Nevzat Can Sener, et al.
Published: (2013-07-01) -
New therapeutic strategies for the treatment of male lower urinary tract symptoms
by: Dimitropoulos K, et al.
Published: (2016-04-01)